Literature DB >> 15121308

HIV risk and prevention in a post-vaccine context.

Peter A Newman1, Naihua Duan, Ellen T Rudy, Kathleen Johnston-Roberts.   

Abstract

Initial HIV vaccines are likely to be only partially efficacious; increased risk behaviors in response to future HIV vaccine availability have the potential to subvert the effectiveness of vaccines in controlling the AIDS epidemic. To assess attitudes, beliefs and behavioral intentions in response to hypothetical availability of FDA-approved HIV vaccines, we conducted 9 focus groups among participants (N = 99; median age = 33 years; 48% female; 22% African American, 44% Latino, 28% White) recruited from STD clinics, needle exchange programs, and Latino community based health organizations, using purposive, venue-based sampling, and interviewed 9 key informant service providers. Data were analyzed using narrative thematic analysis and Ethnograph qualitative software. Participants predicted a "lightening up" of safer sex behaviors among at least half of their peers and, to a lesser extent, a relaxing of safer needle use practices in response to HIV vaccine availability. Both participants and providers urged HIV preventive interventions that: (1) provide education and awareness regarding partial efficacy vaccines, (2) combat the belief in an HIV vaccine as a "magic bullet," and (3) stressed the need for sustained behavioral risk reduction interventions in the face of continued HIV risk and other STDs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121308     DOI: 10.1016/j.vaccine.2003.10.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  A susceptible-infected epidemic model with voluntary vaccinations.

Authors:  Frederick H Chen
Journal:  J Math Biol       Date:  2006-06-07       Impact factor: 2.259

2.  HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion.

Authors:  Kathleen Johnston Roberts; Peter A Newman; Naihua Duan; Ellen T Rudy
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

3.  What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Authors:  Peter A Newman; Naihua Duan; Lisa Kakinami; Kathleen Roberts
Journal:  Vaccine       Date:  2008-03-28       Impact factor: 3.641

4.  Drug users' willingness to encourage social, sexual, and drug network members to receive an HIV vaccine: a social network analysis.

Authors:  A M Young; R J DiClemente; D S Halgin; C E Sterk; J R Havens
Journal:  AIDS Behav       Date:  2014-09

5.  HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics.

Authors:  Peter A Newman; Naihua Duan; Sung-Jae Lee; Ellen T Rudy; Danielle S Seiden; Lisa Kakinami; William E Cunningham
Journal:  Vaccine       Date:  2005-11-21       Impact factor: 3.641

Review 6.  The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention.

Authors:  Mary Jane Rotheram-Borus; Dallas Swendeman; Gary Chovnick
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

7.  HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach.

Authors:  Sung-Jae Lee; Ronald A Brooks; Peter A Newman; Danielle Seiden; Rassamee Sangthong; Naihua Duan
Journal:  AIDS Care       Date:  2008-11

8.  Engaging members of African American and Latino communities in preventive HIV vaccine trials.

Authors:  Magdalena E Sobieszczyk; Guozhen Xu; Krista Goodman; Debbie Lucy; Beryl A Koblin
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

9.  Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences.

Authors:  S J Lee; P A Newman; W S Comulada; W E Cunningham; N Duan
Journal:  Int J STD AIDS       Date:  2012-04       Impact factor: 1.359

10.  Will HIV vaccination reshape HIV risk behavior networks? A social network analysis of drug users' anticipated risk compensation.

Authors:  April M Young; Daniel S Halgin; Ralph J DiClemente; Claire E Sterk; Jennifer R Havens
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.